| タイトル |
-
Up-To-Date Perspectives for Hyperuricemia, Cardiorenal Influence and Urate-Lowering Therapy (ULT)
|
| 作成者 |
|
| 権利情報 |
-
This is an open-access article distributed under the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
| 主題 |
-
Other
Hyperuricemia
-
Other
Urate-Lowering Therapy
-
Other
Selective Urate Reabsorption Inhibitor
-
Other
Chronic Kidney Disease
-
Other
Preventing Early Renal Loss in Diabetes
-
Other
American College of Rheumatology
|
| 内容注記 |
-
Other
Hyperuricemia is a clinical important problem and its prevalence has been increased. Latest topics are described. The guideline adequately managing gout was published from American College of Rheumatology (ACR). Various optimal uses of urate-lowering therapy (ULT) were presented. The cardiorenal effects of hyperuricemia have been investigated for years. Regarding the patients on chronic kidney disease (CKD) and high risk of progression, ULT with allopurinol did not show the decline in eGFR compared to the control. Recently, dotinurad that is a new selective urate reabsorption inhibitor (SURI) would be applied to medical practice. Low-dose dotinurad showed satisfactory pharmacological efficacy.
|
| 出版者 |
Asploro
|
| 日付 |
|
| 言語 |
|
| 資源タイプ |
journal article |
| 出版タイプ |
VoR |
| 資源識別子 |
URI
http://repo.lib.tokushima-u.ac.jp/116090
|
| 関連 |
-
isIdenticalTo
DOI
https://doi.org/10.36502/2021/droa.6178
|
| 収録誌情報 |
-
Diabetes Research : Open Access
-
巻3
号1
開始ページ16
終了ページ19
|
| ファイル |
|
| コンテンツ更新日時 |
2023-06-26 |
